S. 1906 · 118th Congress (2023–2025)
Promising Pathway Act
This bill provides for expedited, provisional approval of drugs for serious or life-threatening diseases or conditions.
Specifically, the bill allows for provisional approval of drugs that are used to treat, prevent, or diagnose a serious or life-threatening disease or condition for which premature death is likely without early medical intervention. The Food and Drug Administration (FDA) must evaluate applications within 90 days of receipt. The FDA may approve applications if there is early evidence, including real-world and real-time evidence, of the drug's efficacy, as well as substantial evidence of the drug's safety. Provisional approval is valid for two years and may be renewed for up to eight years. The FDA may withdraw provisional approval in the event of serious adverse health effects.
Drug sponsors that receive provisional approval must require all patients receiving the drug to participate in an observational registry, through which the drug sponsor may collect and submit data relating to the drug until it is fully approved. Registries may be operated by the drug sponsor or another entity. The FDA must annually review these registries; sponsors of registries that fail to meet the bill's requirements are subject to civil penalties.
Show official title
A bill to amend the Federal Food, Drug, and Cosmetic Act to establish a time-limited provisional approval pathway, subject to specific obligations, for certain drugs and biological products, and for other purposes.
Expired in Senate committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to committee
This bill’s path
This is S. 1906’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed Senate
Passed House
Sent to President
Signed into law
Expired
- Sponsor
- Sen. Mike Braun (R-IN)
- Cosponsors
19 cosponsors
4 original · 15 later
11 R · 8 D
- Sen. Kevin Cramer (R-ND)· Original · Jun 8, 2023
- Sen. Kirsten E. Gillibrand (D-NY)· Original · Jun 8, 2023
- Sen. Lisa Murkowski (R-AK)· Original · Jun 8, 2023
- Sen. Roger F. Wicker (R-MS)· Original · Jun 8, 2023
- Sen. Joe Manchin III (D-WV)· Later · Oct 18, 2023
- Sen. Raphael G. Warnock (D-GA)· Later · Oct 24, 2023
- Sen. Lindsey Graham (R-SC)· Later · Nov 1, 2023
- Sen. Eric Schmitt (R-MO)· Later · Nov 1, 2023
- Sen. J. D. Vance (R-OH)· Later · Nov 1, 2023
- Sen. Alex Padilla (D-CA)· Later · Nov 2, 2023
- Sen. Jeanne Shaheen (D-NH)· Later · Nov 2, 2023
- Sen. Steve Daines (R-MT)· Later · Nov 7, 2023
- Sen. Cynthia M. Lummis (R-WY)· Later · Nov 7, 2023
- Sen. Pete Ricketts (R-NE)· Later · Nov 7, 2023
- Sen. Shelley Moore Capito (R-WV)· Later · Nov 8, 2023
- Sen. Jon Tester (D-MT)· Later · Nov 14, 2023
- Sen. Peter Welch (D-VT)· Later · Dec 7, 2023
- Sen. John Fetterman (D-PA)· Later · Dec 12, 2023
- Sen. John Kennedy (R-LA)· Later · Jan 10, 2024
- Policy area
- Health
- Subjects
- Administrative law and regulatory procedures
- Civil actions and liability
- Congressional oversight
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Health information and medical records
- Prescription drugs
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in Senate
Document: Introduced in Senate
Sources
- Congress.gov action
- Library of Congress
- Latest
Referred to committee
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sources
- Congress.gov action
- Senate
Expired
Introduced → Referred to Senate Health, Education, Labor, and Pensions → No further action before the 118th Congress ended.
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in Senate |
Titles (2)
Promising Pathway Act
Display title, Short title · Introduced in Senate
A bill to amend the Federal Food, Drug, and Cosmetic Act to establish a time-limited provisional approval pathway, subject to specific obligations, for certain drugs and biological products, and for other purposes.
Official title · Introduced in Senate